Thomas Sandgaard Sells 2,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $8.82, for a total transaction of $17,640.00. Following the completion of the transaction, the chief executive officer now owns 14,615,662 shares in the company, valued at approximately $128,910,138.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Price Performance

NASDAQ:ZYXI traded up $0.85 during trading hours on Wednesday, reaching $9.21. The stock had a trading volume of 243,942 shares, compared to its average volume of 172,001. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The stock has a market capitalization of $293.34 million, a PE ratio of 61.40 and a beta of 0.53. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The company has a 50 day moving average price of $8.14 and a two-hundred day moving average price of $9.00.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. During the same period in the previous year, the firm posted $0.10 EPS. The business’s quarterly revenue was up .1% on a year-over-year basis. As a group, sell-side analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zynex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZYXI. Investment Partners Asset Management Inc. bought a new position in shares of Zynex during the 3rd quarter valued at approximately $96,000. Hsbc Holdings PLC bought a new stake in Zynex in the second quarter worth $113,000. Quest Partners LLC boosted its stake in Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after buying an additional 11,195 shares during the period. State Board of Administration of Florida Retirement System bought a new position in Zynex during the first quarter valued at $137,000. Finally, Principal Financial Group Inc. increased its position in Zynex by 10.4% during the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock valued at $182,000 after acquiring an additional 1,846 shares during the last quarter. 29.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZYXI. Royal Bank of Canada reduced their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright boosted their price target on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.